BioMedNewsBreaks

WednesdayJan 29, 2020 10:15 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for thyroid carcinoma. Genprex has no affiliation with these researchers. The study, published in the International Journal of Molecular Sciences, reports that TUSC2 overexpression decreased thyroid cancer proliferation, migration and invasion. “We continue to be encouraged by data resulting from studies conducted at multiple research institutions…

Continue Reading

TuesdayJan 28, 2020 1:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual…

Continue Reading

TuesdayJan 28, 2020 9:18 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its common stock at a price of $1.05 each, resulting in total gross proceeds of $8 million before deducting commissions and estimated offering expenses. The company plans to use the proceeds toward the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and…

Continue Reading

FridayJan 24, 2020 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will assist in fast-tracking the commercialization of its AI-driven technology and services. Subject to the negotiation of a definitive agreement and other terms and conditions, the transaction is anticipated to be completed within the first two quarters of 2020. “Our goal is to provide researchers in…

Continue Reading

ThursdayJan 23, 2020 11:49 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock. According to the update, the offering is priced at-the-market under Nasdaq rules with par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering. Gross proceeds will be approximately $8,000,000 before deducting fees and other estimated offering expenses,…

Continue Reading

TuesdayJan 21, 2020 10:28 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso(R)). Tagrisso(R), with worldwide sales of $1.86 billion in 2018 and $2.31 billion in the first 9 months of 2019, is currently AstraZeneca’s highest grossing product for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone. Genprex has treated more…

Continue Reading

FridayJan 17, 2020 3:32 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://nnw.fm/y6fnc). Per the update, the company intends to have its first predictive model of ovarian cancer prepared for initial commercialization in the first quarter of 2020. An article discussing the company reads, “‘We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive…

Continue Reading

MondayJan 06, 2020 1:05 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam Prior, CPA, to its Board of Directors. According to the update, Prior is the founder and CEO of Priorities Group, Inc., a provider of CFO services to small and mid-sized businesses, and has approximately 35 years of previous experience in accounting, predominantly in management as a chief financial officer and controller. “Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board…

Continue Reading

MondayJan 06, 2020 11:05 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco Union Square in San Francisco from January 13–15, 2020. Genprex’s President and COO, Julien Pham, MD, MPH, will lead its presentation, scheduled for Monday, January 13 at 11:30 a.m. PT (2:30 p.m. ET); Track: Yosemite C (Ballroom Level). In addition, Pham and the company’s CEO, Rodney Varner, will be available for one-on-one investor meetings. “We are…

Continue Reading

ThursdayNov 21, 2019 9:32 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $1.26M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurrent private placement, Genprex agreed to issue unregistered warrants to purchase up to 3,167,986 shares to the investors in the registered direct offering. The warrants, which have an exercise price of $0.46 per share, will be exercisable six months from the issuance date and will expire after five years. The warrants will be exercisable for…

Continue Reading